Get the Stockscreener App
5.89
4.62%
0.26
After Hours:
1.90
-3.99
-67.74%
Exicure Inc stock is traded at $5.89, with a volume of 59,361.
It is up +4.62% in the last 24 hours and up +20.20% over the past month.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.
See More
Previous Close:
$5.63
Open:
$5.75
24h Volume:
59,361
Relative Volume:
0.10
Market Cap:
$37.54M
Revenue:
$500.00K
Net Income/Loss:
$-7.88M
P/E Ratio:
-3.477
EPS:
-1.694
Net Cash Flow:
$-5.49M
1W Performance:
+7.09%
1M Performance:
+20.20%
6M Performance:
-13.13%
1Y Performance:
-54.13%
1-Day Range:
$5.66
$6.02
1-Week Range:
$5.3106
$6.02
52-Week Range:
$3.1006
$15.91
Exicure Inc Stock (XCUR) Company Profile
Name
Exicure Inc
Sector
Industry
Phone
847-673-1707
Address
2430 N. HALSTED ST., CHICAGO, IL
Compare XCUR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.625 | 0 | 0 | 0 | 0 | 0.00 | |
GOODO
Gladstone Commercial Corporation
|
20.83 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
4.82 | 418.21M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
SHMD
Schmid Group N V
|
7.30 | 329.86M | 0 | 0 | 0 | 0.00 |
|
DWLD
Davis Select Worldwide ETF
|
48.05 | 0 | 0 | 0 | 0 | 0.00 |
|
QQQE
Direxion NASDAQ-100 Equal Weigh
|
105.25 | 0 | 0 | 0 | 0 | 0.00 |
Exicure Inc Stock (XCUR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-18-20 | Initiated | BMO Capital Markets | Outperform |
| Nov-20-19 | Initiated | Guggenheim | Buy |
Exicure Inc Stock (XCUR) Latest News
Avoiding Lag: Real-Time Signals in (XCUR) Movement - Stock Traders Daily
Bond Watch: Why Exicure Inc 2H0 stock attracts HNW investorsWeekly Loss Report & Low Volatility Stock Suggestions - moha.gov.vn
Aug Highlights: Is Exicure Inc 2H0 stock worth buying before Fed actionWeekly Risk Report & Verified Short-Term Trading Plans - moha.gov.vn
Exicure (XCUR) Stock Soars on Burixafor Phase 2 Data: What December 2025 Investors Need to Know - ts2.tech
Promising Biotech Stocks To Keep An Eye OnDecember 9th - MarketBeat
Buyback Watch: Is Exicure Inc 2H0 stock worth buying before Fed action2025 Key Highlights & Free Fast Gain Swing Trade Alerts - moha.gov.vn
Exicure Regains Nasdaq Compliance as of July 2025 - The Globe and Mail
Trading Action: Why Exicure Inc stock is rated strong buyAnalyst Downgrade & Free High Accuracy Swing Entry Alerts - moha.gov.vn
(XCUR) Risk Channels and Responsive Allocation - Stock Traders Daily
Exicure presents topline data from burixafor combination trial - MSN
Will Exicure Inc. stock benefit from upcoming earnings reportsM&A Rumor & Accurate Intraday Trading Signals - DonanımHaber
Is Exicure Inc. stock ready for breakoutMarket Trend Review & Technical Confirmation Trade Alerts - ulpravda.ru
Exicure stock soars 40% after stem cell drug helps most patients hit phase 2 goal — traders call it 'cheap' at current levels - MSN
Trading the Move, Not the Narrative: (XCUR) Edition - Stock Traders Daily
Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Exit Recap: Will Exicure Inc stock recover faster than marketSwing Trade & Real-Time Chart Pattern Alerts - moha.gov.vn
Promising Biotech Stocks To Keep An Eye On – December 9th - Defense World
Sangsangin investment sells Exicure (XCUR) shares worth $3.77 million By Investing.com - Investing.com Nigeria
XCUR Insider Trading - Quiver Quantitative
Sangsangin Investment & Securities Sells All Exicure Shares - TradingView — Track All Markets
Shareholder Sangsangin Investment & Securities Co Ltd Sells 433,332 ($3.8M) Of Exicure Inc [XCUR] - TradingView — Track All Markets
Exicure’s Risky Bet On Stem Cell Mobilization Pays Early Dividends - Finimize
Morning Market Movers: ASPC, ENVB, AFJK, JXG See Big Swings - RTTNews
Exicure’s Stunning Rise: What’s Fueling It? - StocksToTrade
Exicure Shares Surge 41% On Promising Phase 2 Data For Multiple Myeloma Drug - Nasdaq
Exicure Stock Soars 40% After Stem Cell Drug Helps Most Patients Hit Phase 2 Goal — Traders Call It ‘Cheap’ At Current Levels - Stocktwits
Exicure Rally Fueled By Rapid Cell-Boosting Results In Blood Cancer Trial - Benzinga
Top Gainers on the US Stock Market Today (December 9, 2025): AFJK, NCPL, XCUR, ALEX and More Surge as Fed Meeting Looms - ts2.tech
Exicure (XCUR) Stock: Biotech Soars on Promising Cancer Drug Data - parameter.io
ASH: Exicure rebounds with phase 2 win, seeing 90% blood cell mobilization in myeloma - Fierce Biotech
Dow Surges Over 100 Points; Campbell's Posts Upbeat Earnings - Benzinga
This BlackRock stock just rocketed 70% - Finbold
Exicure (XCUR) Stock: Biotech Shares Surge 140% on Cancer Drug Breakthrough - Blockonomi
Exicure Inc.: Is It a Bet Worth Taking? - timothysykes.com
Exicure Inc (XCUR) expanding its growth trajectory ahead - setenews.com
Pre Market Movers: XCUR, VOR, MTVA Set The Path - RTTNews
Morning Market Movers: ATMC, XCUR, VOR, ATMV See Big Swings - RTTNews
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Exicure Soars On Burixafor Data In Multiple Myeloma Trial - Nasdaq
Exicure Inc. (XCUR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
After-Hours Gainers: Exicure Tops List With 72% Jump, Wave Life And Assembly Biosciences Advance - Nasdaq
Exicure (XCUR) Sees Positive Phase 2 Trial Results for Burixafor in Multiple Myeloma - GuruFocus
Exicure reports positive Phase 2 results for multiple myeloma therapy By Investing.com - Investing.com Nigeria
Exicure Inc Stock (XCUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):